Claus Andersson Email & Phone Number

Copenhagen, Capital Region, DK

Sunstone - Life Science VenturesInvesting in development of prescription drugs based on new chemical entities and active pharmaceutical ingredients that work according to a well described and evidenced biological/molecular mechanism of action. Working with founders, management, co-investors and advisors to develop our portfolio companies to become valuable.

Turin, Piedmont, IT

Resalis Therapeutics’ is based on its unique scientific understanding of the non-coding RNA drug modality and a new biological mechanism of action that enables a therapy for obese that preserves muscle mass to provide a sustainable and durable weight loss effect. The company is starting clinical trials in obese patients in 2024.Building on robust.

Marseille, FR

DiogenX is a preclinical stage biotech company committed to discover and develop innovative biologics as new therapeutics options for millions of diabetic patients around the world. Focus is on developing a first-in-class regenerative treatment for type 1 diabetes to normalize the lives of patients.

Heverlee, Flemish Region, BE

Rewind is an early-stage biotech company developing a poential therapy for Multiple Sclerosis. Rewind is focused on restoring and protecting the myelin sheet around the nerves in the brain. Loss of myelin can occur for various reasons, e.g., aging, in response to altered neuronal activity, brain injury or disease. The CNS contains a population of stem.

Hanover, Lower Saxony, DE

Cardior was acquired by Novo Nordisk on May 2nd, 2024. Cardiac dysfunction remains the leading cause of death world-wide, and heart diseases represent a global and increasing burden with prevalence and mortality rates far exceeding those of other diseases. Cardior is based on substantial academic research and proprietary preclinical work in exactly this.

Brussels, BE

Contribution of input to the editorial process of sections in the Invest Europe Handbook of Professional Standards (https://www.investeurope.eu/industry-standards/professional-standards) providing a practical guidance on the principles of governance, transparency and accountability and focusing on the relationship between fund managers and their investors.

Copenhagen, Denmark, DK

IO Biotech Inc. is a clinical stage biotech company developing disruptive immune therapies i.e. therapeutic cancer vaccines. The company is in Phase 3 pivotal studies in melanoma with outstanding results, and we have listed the company on NASDAQ New York. It is therefore time to leave this board to spend time on new exciting investments.

Forendo was acquired by Organon in 2021. Forendo Pharma is a clinical stage drug development company, with core competencies in tissue specific hormone mechanisms and therapeutic focus in women’s health. World leading innovator in the endometriosis field, with two active programs. The company was acquired by Organon in December 2021.

Lund, Skåne County, SE

Cantargia AB is listed on NASDAQ main market in Stockholm. The company develops new pharmaceutical treatments against cancers based on anti-body molecules and has particular focus on the target IL1RAP.

Malmö, Skane County, SE

Acarix has developed and commercialized the CADScor® System which combines world class acoustic knowledge and advanced algorithms into a new method for non-invasively obtaining the patient specific CADScore (Coronary Artery Disease Score) in less than 8 minutes. Doctors and specialists use the CADScore to estimate the risk of having occlusions in the.

Follicum AB is a listed company. The company develops new pharmaceutical treatments aiming to help people that suffer from hair growth disorders. The molecules originate from an invention based on molecules that stimulate regrowth of hair helping people that suffer from hair loss (alopecia).

Brussels, BE

Advisor to the European Commission on Horizon2020 'Access to Risk Finance'

DK

Precisense A/S was active in the field of semi-invasive glucose monitoring by way of a subcutaneous passive sensor. Completed a structured transaction selling of assets to Medtronic Inc. April 2009.

Santaris Pharma (now Roche Innovation Centre) developed drugs for the treatment of cancer, infectious and metabolic diseases utilizing the proprietary LNA (locked nucleic acid) technology. Acted as Sellers Representative during negotiations with Roche. Sold to Roche September 2014 at a total of 450 MUSD.

JenaValve manufactures a transcatheter aortic valve implantation (TAVI) system for implantation of heart valves. The 3-feeler element includes the ability to reposition the JenaValve™ in the aorta during the implantation procedure, thus ensuring a correct and precise subcoronary, anatomical positioning within the native valve.

Jurag Separation developed a highly efficacious ultrafiltration system for manufacturing of high-values drugs and extracts. Acted as representative on behalf of sellers when selling the company to an undisclosed NASDAQ:OMX C20 corporation.

Scancell A/S was a first initiative to drive immuno-oncology through the clinic.

Copenhagen, Capital Region Of Denmark, DK

Brønshøj, DK

Manager of the R&D section and sensor technology development

København K, DK

Postdoc in multivariate statistics

Doctor Of Philosophy (Phd), Multivariate Statistics - Chemometrics

Msc, Chemical Engineering